Sonya Negley, IOM, CSMA, reviews how patient advocates can help patients newly diagnosed with metastatic breast cancer.
Sonya Negley, IOM, CSMA: I think the most important thing for patient advocates and patient advocacy organizations is to make sure that we have the correct, most recent data. The information about new treatment options coming to market can be overwhelming, and while it can be protracted, it also comes to market quickly. So, it’s important we as patient advocacy organizations have a good idea of what that means and what that means for the patients. The best thing individual patient advocates can do is get involved, and have a voice in what is going on with metastatic breast cancer.
For a lot of people who have cancer in general, most of their treatment options are pretty straightforward, and for the most part, their cancer can be contained or cured. But in metastatic breast cancer, that’s not where we are yet. We are at a point where there are a lot of discoveries happening, a lot of personalized medicine; however, it’s not a disease that is not terminal. It’s not chronic, it’s not curable. So, the best thing patient advocates can do is share their voice, share the importance of research. It is paramount that we fund research to make sure we can get to those good treatment options or treatment bridges, and hopefully soon, have a discovery that will render this disease survivable. Sharing stories of what they’ve gone through [is important]. Not necessarily saying to another patient that their journey equals the newly diagnosed journey, but rather, sharing their experiences so others can understand that you can have a good quality of life, and there are lessons [to be] learned from other patient advocates.
Transcript edited for clarity
Trastuzumab Biosimilar Gets Go Ahead in EU for HER2+ Breast and Metastatic Gastric Cancers
December 5th 2023EG12014, a biosimilar of the anti-HER2 monoclonal antibody trastuzumab, has received a marketing authorization from the European Commission for use in the European Union (EU) for the treatment of patients with HER2-positive (HER2+) breast and metastatic gastric cancer; these are the same indications that trastuzumab holds in the European Union.
Read More
Emily Goldberg Shares Insights as a Genetic Counselor for Breast Cancer Risk Screening
October 30th 2023On this episode of Managed Care Cast, Emily Goldberg, MS, CGC, a genetic counselor at JScreen, breaks down how genetic screening for breast cancer works and why it is so important to increase awareness and education around these screening tools available to patients who may be at risk for cancer.
Listen
The FDA has approved capivasertib plus fulvestrant for the treatment of patients with HR-positive, HER2-negative, locally advanced or metastatic breast cancer harboring 1 or more PIK3CA, AKT1, or PTEN alteration, following progression on at least 1 endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.
Read More
The Disproportionate Impact of the Pandemic on Health Care Disparities and Cancer
February 22nd 2022On this episode of Managed Care Cast, we discuss how already wide health care inequities in cancer are becoming much worse because of the COVID-19 pandemic, with guest Monica Soni, MD, associate chief medical officer at New Century Health.
Listen